{"id":"https://genegraph.clinicalgenome.org/r/3195177b-32e5-4c11-85bd-fe59f2e391aev1.0","type":"EvidenceStrengthAssertion","dc:description":"There is abundant evidence published associating the XPA gene with xeroderma pigmentosum group A since the gene-disease relationship was first proposed by Tanaka et al. (1990). Multiple case level studies have been performed with XPA patients that have variants in the XPA gene. 8 complementation groups genes (XPA, XPB, XPC, XPD, XPE, XPF, XPG, and XP variant (XPV)) in Nucleotide excision repair (NER) pathway were reported to cause Xeroderma Pigmentosum. Multiple Xpa deficient mouse models have been established to show consistent phenotypes with XPA patients, including growth retardation, abnormal behavior, premature aging and UV or chemical induced skin tumours. All of these types of evidence are consistent with a definitive relationship between the XPA gene and xeroderma pigmentosum group A.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/3195177b-32e5-4c11-85bd-fe59f2e391ae","GCISnapshot":"https://genegraph.clinicalgenome.org/r/5cd298eb-1e1a-4283-851e-2dd24059ba22","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/5cd298eb-1e1a-4283-851e-2dd24059ba22_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2018-11-02T21:36:51.734Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/5cd298eb-1e1a-4283-851e-2dd24059ba22_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2020-09-01T00:00:00Z","role":"Publisher"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5cd298eb-1e1a-4283-851e-2dd24059ba22_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5cd298eb-1e1a-4283-851e-2dd24059ba22_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e6825942-13c8-4a7f-9112-82a212706b4d","type":"EvidenceLine","dc:description":"XPA/TTD double-mutant mice","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5db0f9e6-5be8-42ae-bc36-2a4d1cb70323","type":"Finding","dc:description":"TTD mice carrying an additional mutation in XPA, which enhances the DNA repair defect, showed a greatly accelerated aging phenotype, which correlated with an increased cellular sensitivity to oxidative DNA damage.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11950998","rdfs:label":"Premature Aging in Mice Deficient in DNA Repair","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/9b06f3c1-a16e-4929-93be-6a4c7462abc4","type":"EvidenceLine","dc:description":"Comparable findings were independently reported by de Vries et al. (1995).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/883365bc-ac2e-4964-b9e7-125982bd8a52","type":"Finding","dc:description":"The XPA-deficient mice were defective in NER and highly susceptible to ultraviolet-B- or 9,10-dimethyl-1,2-benz[a]anthracene-induced skin carcinogenesis. These findings provide in vivo evidence that the XPA protein protects mice from carcinogenesis initiated by ultraviolet or chemical carcinogen.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7675085","rdfs:label":"UV or chemical induced skin tumours in Xpa-deficient mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/dd36a4f0-7b33-43d0-9651-85698d4425f0","type":"EvidenceLine","dc:description":"XPA -/- CSB -/-  mice double knock out mice also with CSB gene loss.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6e9754da-1309-4f7f-bb3a-5b74e832cb9f","type":"Finding","dc:description":"Mice lacking both the Xpa and the Csb genes show growth retardation and abnormal behavior closely resembling symptoms observed in human XPA and/or CSB patients at an early postnatal stage.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11687625","rdfs:label":"Growth retardation and abnormal behavior in XPA-/-CSB-/-mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/5cd298eb-1e1a-4283-851e-2dd24059ba22_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5e966421-2d47-46e4-a2fa-f6fc0c2492ea","type":"EvidenceLine","dc:description":"Eight genes","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d16a0599-517e-4330-902e-1e1be16f8c7a","type":"Finding","dc:description":"8 complementation groups genes (XPA, XPB, XPC, XPD, XPE, XPF, XPG, and XP variant (XPV)) in Nucleotide excision repair (NER) pathway cause Xeroderma Pigmentosum.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24105368","rdfs:label":"8 complementation groups genes cause Xeroderma Pigmentosum","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6},{"id":"https://genegraph.clinicalgenome.org/r/5cd298eb-1e1a-4283-851e-2dd24059ba22_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d6862a96-0a0e-4743-8dda-be8997a7011e_proband_score_evidence_line","type":"EvidenceLine","dc:description":"In 19 of 20 Japanese patients with xeroderma pigmentosum complementation group A, Tanaka et al. (1990) identified a G-to-C transversion at the 3-prime splice acceptor site of intron 3 of the XPA gene. Satokata et al. (1990) found that the G-to-C transversion abolished the canonical 3-prime splice site and created 2 abnormally spliced mRNA forms. Using the AlwNI RFLP, Satokata et al. (1990) found that 16 of 21 unrelated Japanese patients with XP were homozygous and 4 were heterozygous for this mutation. Cleaver et al. (1995) stated that homozygosity for the G-to-C transversion at the 3-prime acceptor site of intron III/exon IV of the XPA gene represents 80 to 90% of Japanese patients with XPA. This is a common founder variant in Japanese population.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5c68256b-f56e-4d61-ae49-39a7f5c12326","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/2234061","rdfs:label":"Japanese patients","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0008069","obo:HP_0000992"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/d6862a96-0a0e-4743-8dda-be8997a7011e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/2234061","allele":{"id":"https://genegraph.clinicalgenome.org/r/89111309-0160-411f-8bfa-3c779b69e469","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"XPA, IVS3AS, G-C","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/992"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/99bc1d4c-d18e-4355-9e68-663560e41bf0_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Homozygosity for a nucleotide transition in the XPA gene, resulting in an arg207-to-ter (R207X) substitution. Two star variant in ClinVar.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cadf61a7-d584-4bc5-9311-5cfb59181da5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1372102","rdfs:label":"XP12RO","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0000992","obo:HP_0008069"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/99bc1d4c-d18e-4355-9e68-663560e41bf0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1372102","allele":{"id":"https://genegraph.clinicalgenome.org/r/3ede36ee-5664-46ff-88ad-795b7591e4f3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000380.3(XPA):c.619C>T (p.Arg207Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/996"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/d36cca73-88f9-44f8-b195-04a7b8c4c433_proband_score_evidence_line","type":"EvidenceLine","dc:description":"A C deletion at nucleotide 374 causing frameshift.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/08c7cb2a-31c3-47c6-9aaa-dfb03857404f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1339397","rdfs:label":"GM2990","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0008069","obo:HP_0000992"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/d36cca73-88f9-44f8-b195-04a7b8c4c433_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1339397","allele":{"id":"https://genegraph.clinicalgenome.org/r/2270a737-868d-4fcc-b3bf-83710d6e6166","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000380.3(XPA):c.374del (p.Thr125IlefsTer15)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658820946"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/3e411870-c2e8-48db-aea6-aee071294aaf_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Compound heterozygosity for 2 mutations in the XPA gene: a 323G-T transversion resulting in a cys108-to-phe (C108F) substitution that disrupted a putative zinc finger domain, and a 5-bp deletion causing a frameshift and premature termination.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d3c5093f-98a1-4000-a098-ae7a1e721939","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1339397","rdfs:label":"GM2009","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0000992","obo:HP_0008069"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/3e411870-c2e8-48db-aea6-aee071294aaf_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1339397","allele":[{"id":"https://genegraph.clinicalgenome.org/r/13fa1645-7a4f-484f-94a6-4ca88dae8576","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000380.3(XPA):c.349_353delCTTAT (p.Leu117Glufs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/994"}},{"id":"https://genegraph.clinicalgenome.org/r/b33ea61c-d44a-4d89-9caf-529faef390a1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000380.3(XPA):c.323G>T (p.Cys108Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/993"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/c1133416-1e1f-4918-81fd-b346740ce5b8_proband_score_evidence_line","type":"EvidenceLine","dc:description":"A T-to-A transversion in the XPA gene, resulting in a tyr116-to-ter (Y116X) substitution in 2 unrelated Japanese patients with severe XPA. Maeda et al. (1995) reported that a patient who was homozygous for the Y116X mutation had never walked unaided.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cc0b2192-ed90-4efa-ba42-9e9a5a4c2e3d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1372102","rdfs:label":"2 unrelated Japanese patients","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0000992","obo:HP_0008069"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/c1133416-1e1f-4918-81fd-b346740ce5b8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1372102","allele":{"id":"https://genegraph.clinicalgenome.org/r/b88188c1-14ba-444e-9a73-5637817be5a8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000380.3(XPA):c.348T>A (p.Tyr116Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/997"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/ee67582b-fd38-4db7-8837-96bbd8d3c1c2_proband_score_evidence_line","type":"EvidenceLine","dc:description":"A C-to-T transition in exon 6 of the XPA gene, resulting in an arg228-to-ter (R228X) substitution. Of 21 unrelated XPA patients examined, 1 was homozygous for this mutation and 3 were compound heterozygotes for this mutation and a splice site mutation in intron 3. Nishigori et al. (1993) found that 6 of 7 Tunisian XPA patients had the R228X mutation.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/83d07b0c-f2fd-44df-ba22-7f6fa25bfd02","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1372102","rdfs:label":"XP39OS","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0008069","obo:HP_0000992"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/ee67582b-fd38-4db7-8837-96bbd8d3c1c2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1372102","allele":{"id":"https://genegraph.clinicalgenome.org/r/bad953e8-18a9-40a5-8065-fd95e9438226","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000380.3(XPA):c.682C>T (p.Arg228Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/995"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":491,"specifiedBy":"GeneValidityCriteria6","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/B5b_eoutGb0","type":"GeneValidityProposition","disease":"obo:MONDO_0010210","gene":"hgnc:12814","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_5cd298eb-1e1a-4283-851e-2dd24059ba22-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}